Recognizing the risk of Propofol-related infusion syndrome (PRIS) with propofol, we are looking to learn what safety measures health systems have implemented around the use of propofol. I would appreciate your responses to the following questions and any additional feedback:

Hello all,

Had a question for you guys. If not willing to discuss in the thread, I'd definitely be willing to schedule a discussion off line.

We are planning to open an ambulatory surgical center in the next 2 years. We are curious to know how like size (722 bed) academic medical centers with ambulatory surgical centers handle the compounding of hazardous medications at these locations. (i.e. – compound on site at ASC in hazardous cleanroom, or compound offsite and deliver to ASC).

Thanks!
Jameika

I'm wondering if anyone would like to share any policies they may have with respect to transportation of medications (controlled and/or non-controlled) to/from patients' homes. Examples might include OPAT programs or palliative care home care clients. Do you allow staff (pharmacists, nurses and/or unregulated healthcare professionals) to transport medications under any circumstances? Anything you could share would be very much appreciated.

Thanks
Rebecca Ellis
Home Care Pharmacist
Health PEI
Canada

Is anyone aware of any changes needed with the new "PS-Mycophenolate REMS program" approved 6/1/2023?

In comparison to the old REMS, the goals are the same and the prescriber form states "If you have previously completed the requirements of another Mycophenolate REMS, it is not necessary to complete the PS-Mycophenolate REMS.

I am a little confused as to why there is a second REMS program? Does not appear that the old one was removed or that providers need to resubmit a new prescriber training form. Maybe I am missing something?

Please help the GEDSA ENFit clinical advisory board assess conversion status by completing the following quick survey

https://forms.office.com/Pages/ResponsePage.aspx?id=WGRxUhS5HU61dYwQBPPs...

How does your institution calculate IBW for patients less than 5 feet tall?
How does your institution calculate IBW for patients with amputations
What formula do you currently use (growth charts, Traub formula, etc.)?

Interested in how other institutions have built their sterile water 10ml order sentences to reflect that it is for diluent use only. What route have you used in the orderable? I am thinking that we may need to build a new route of "diluent", "other" or "misc" for safety purposes to reflect that the SW itself should not be given IV Push without using as a diluent first. Appreciate any feedback.

Heather

Good afternoon,
Our pediatric outpatient dialysis centers see both children and young adults and have changed practices several times over the years in regards to lock solutions for their hemodialysis catheters. Currently they are using alteplase to each lumen at each session. I wanted to poll the group on the following:
1. What population(s) is/are seen in your outpatient dialysis center(s)?
2. What is the standard lock solution used for hemodialysis catheters?
3. If heparin, what concentration are you utilizing?

Good afternoon,
I am wondering if you can share your thoughts on this Joint Commission requirement: "Medications are dispensed in the most ready-to-administer forms commercially available and, if feasible, in unit doses that have been repackaged by the pharmacy or licensed repackager."

Hi All,

Can those of you who work at health-systems with multiple inpatient sites on one instance of Epic share your approach to High Alert medications? Specifically,

1) Do you have one shared list or does each site have their own?
2) Do you leverage your EMR-generated labels to designate those meds that are High Alert? How does this work if you have one list?